AUTL on Nasdaq
Autolus Therapeutics
Company in London, United Kingdom.1
Price unavailable
Last updated Oct 16, 2026.
Overview
2014Founded1
Compare with Recursion Pharmaceuticals, Cellectis or Compugen Ltd., or pick any stock.
- TickerAUTL on Nasdaq1
- IndustryBiological Products, (No Diagnostic Substances)1
- HeadquartersX01
- Websitewww.autolus.com
- Legal formpublic limited company1
- Incorporated inUnited Kingdom3
- Business addressThe Mediaworks, 191 Wood Lane, London, X0 W12 7Fp3
- Filer categoryNon-accelerated filer, Smaller reporting company3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-358.9%Operating margin4
-381.4%Net margin4
644.9%Revenue growth, 20254
-161.4%Return on equity4
-$302.6MFree cash flow4
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product brought in 99% of the revenue Autolus Therapeutics broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Product | $0 | $74.3M |
| License | $10.1M | $1.1M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue25¢$96.4M
- Research and development31¢$117.7M
- Selling, general and admin34¢$131.9M
- Interest10¢$36.7M
- Income tax1¢$2.0M
Out of $75.4M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total revenue, net | $75.4M | $10.1M |
| Cost of sales | -$96.4M | -$11.4M |
| Research and development expenses, net | -$117.7M | -$138.4M |
| Selling, general and administrative expenses | -$131.9M | -$101.7M |
| Loss from operations | -$270.5M | -$241.4M |
| Other income, net | $515.0K | $220.0K |
| Foreign exchange gains (losses), net | $2.2M | -$989.0K |
| Interest income | $19.0M | $32.4M |
| Interest expense, net | -$36.7M | -$9.3M |
| Total other income (expenses), net | -$15.0M | $22.3M |
| Net loss before income tax | -$285.6M | -$219.1M |
| Income tax expense | -$2.0M | -$1.5M |
| Net loss | -$287.5M | -$220.7M |
| Foreign currency exchange translation adjustment | $23.3M | $135.0K |
| Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0 and $0 | $475.0K | -$317.0K |
| Total other comprehensive income (loss), net of tax | $23.8M | -$182.0K |
| Total comprehensive loss | -$263.7M | -$220.8M |
| Basic net loss per ordinary share (in usd per share) | -$1.08 | -$0.86 |
| Diluted net loss per ordinary share (in usd per share) | -$1.08 | -$0.86 |
| Weighted-average basic ordinary shares (in shares) | 266.1M shares | 255.2M shares |
| Weighted-average diluted ordinary shares (in shares) | 266.1M shares | 255.2M shares |
| Unrealized holding gains (losses) on available-for-sale debt securities, tax | $0 | $0 |
Every line of the balance sheet in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $104.1M | $227.4M | |
| Marketable securities - Available-for-sale debt securities | $196.6M | $360.6M | |
| Restricted cash | $1.5M | $1.4M | |
| Accounts receivable, net | $24.0M | $15.0K | |
| Inventories, net | $33.2M | $4.1M | |
| Prepaid expenses and other current assets | $76.5M | $67.3M | |
| Total current assets | $435.9M | $660.9M | |
| Property and equipment, net | $63.6M | $49.6M | |
| Intangible assets, net | $19.8M | $12.4M | |
| Prepaid expenses and other non-current assets | $249.0K | $170.0K | |
| Operating lease right-of-use assets, net | $64.9M | $55.5M | |
| Long-term deposits | $1.0M | $963.0K | |
| Deferred tax asset | $3.6M | $3.2M | |
| Total assets | $589.1M | $782.7M | |
| Accounts payable | $3.1M | $2.0M | |
| Accrued expenses and other liabilities | $55.8M | $52.3M | |
| Operating lease liabilities, current | $4.6M | $3.0M | |
| Liabilities related to future royalties and milestones, net - current | $10.0M | $3.5M | |
| Total current liabilities | $73.4M | $60.7M | |
| Operating lease liabilities, non-current | $66.8M | $49.6M | |
| Liabilities related to future royalties and milestones, net - non-current | $270.2M | $244.6M | |
| Other long-term payables | $477.0K | $426.0K | |
| Total liabilities | $410.9M | $355.4M | |
| Additional paid-in capital | $1.6B | $1.6B | |
| Accumulated other comprehensive loss | -$5.4M | -$29.2M | |
| Accumulated deficit | -$1.4B | -$1.1B | |
| Total shareholders' equity | $178.1M | $427.3M | $111.5M |
| Total liabilities and shareholders' equity | $589.1M | $782.7M |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$287.5M | -$220.7M |
| Depreciation on property and equipment | $8.3M | $7.6M |
| Amortization of intangible assets | $1.5M | $162.0K |
| Inventory reserves and write-offs | $12.3M | $0 |
| Loss on disposal of property and equipment | $14.0K | $223.0K |
| Share-based compensation net of amounts capitalized | $14.4M | $15.5M |
| Interest expense accrued on liabilities related to future royalties and milestones, net | $36.4M | $8.9M |
| Accretion of available-for-sale securities | -$8.2M | -$1.3M |
| Foreign exchange differences | -$3.2M | $1.9M |
| Non-cash operating lease expense | -$5.7M | $4.7M |
| Loss on termination of operating lease | $0 | $176.0K |
| Impairment of operating lease right-of-use assets and related property and equipment | $349.0K | $414.0K |
| Deferred income tax | -$286.0K | -$185.0K |
| Increase in prepaid expenses and other current assets | -$4.3M | -$33.5M |
| (Increase) decrease in prepaid expenses and other non-current assets | -$266.0K | $938.0K |
| Increase in inventories, net | -$40.2M | -$4.2M |
| Increase in accounts receivable, net | -$24.2M | $0 |
| Decrease in long-term deposits | $0 | $5.0K |
| Increase in accounts payable | $1.3M | $1.6M |
| Increase in accrued expenses and other liabilities | $1.0M | $11.9M |
| Increase (decrease) in operating lease liability | $14.6M | -$369.0K |
| Net cash used in operating activities | -$283.6M | -$206.3M |
| Acquisition of property and equipment | -$19.0M | -$22.1M |
| Acquisition of intangibles assets | -$8.1M | -$12.7M |
| Purchases of marketable securities: available-for-sale debt securities | -$242.6M | -$359.7M |
| Proceeds from maturities and redemptions of marketable securities: available-for-sale debt securities | $428.2M | $0 |
| Net cash provided by (used in) investing activities | $158.5M | -$394.6M |
| Proceeds from issuance of ordinary shares | $0 | $550.0M |
| Proceeds from exercise of share options | $0 | $602.0K |
| Proceeds from liabilities related to future royalties and milestones, net | $0 | $70.0M |
| Payments of equity issuance costs | $0 | -$29.4M |
| Payments of issuance costs related to the liabilities related to future royalties and milestones, net | $0 | -$1.7M |
| Payments of revenue share | -$4.3M | $0 |
| Net cash (used in) provided by financing activities | -$4.3M | $589.6M |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | $6.3M | -$261.0K |
| Net decrease in cash, cash equivalents and restricted cash | -$123.2M | -$11.5M |
| Cash paid for income taxes | $2.0M | $2.4M |
| Property and equipment purchases included in accounts payable or accrued expenses | $1.2M | $1.8M |
| Leased assets terminated and obtained in exchange for operating lease liabilities, net | $0 | -$975.0K |
| Leased assets obtained in exchange for operating lease liabilities | $9.5M | $1.7M |
| Capitalized share-based compensation, net of forfeitures | $76.0K | $3.0K |
| Capitalized implementation costs included in accrued expenses | $130.0K | $816.0K |
Subsidiaries and ownership
Owners
- Syncona 30.6%
- PPF Capital Partners Fund 21%
From Wikidata.1
Former names
- Autolus Therapeutics LtdFeb 9, 2018 to Jun 8, 20183
Timeline
Recent filings
- Sep 22, 2026424B3
- Sep 22, 2026EFFECT
- Sep 15, 2026DEL AM
- Sep 14, 2026S-3
- Sep 3, 20264 PRIMARY DOCUMENT
- Sep 2, 2026144
- Aug 28, 2026SCHEDULE 13D/A
- Aug 14, 2026SCHEDULE 13G/A
- Aug 11, 20268-K
- Aug 11, 202610-Q
- Aug 3, 20268-K
- Aug 3, 20268-K
- Jul 1, 20264 PRIMARY DOCUMENT
- Jul 1, 20264 PRIMARY DOCUMENT
- Jul 1, 20264 PRIMARY DOCUMENT
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitewww.autolus.com1
- WikidataQ56583577
- SEC EDGARCIK 1730463
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataAutolus Therapeutics on Wikidata
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12